News | Radiopharmaceuticals and Tracers | October 28, 2016

New Report Finds U.S. Supply of Critical Medical Isotope Vulnerable

Report documents status of transition from high-enriched to low-enriched uranium targets during production

NAS report, National Academies of Sciences Engineering and Medicine, Mo-99 production, highly enriched uranium, HEU, SNMMI

October 28, 2016 — The National Academies of Sciences, Engineering, and Medicine (NAS) have released a report on the state of molybdenum-99 (Mo-99) production, its utilization in medicine, and progress toward eliminating the use of highly enriched uranium (HEU) during production.

The report was mandated by the American Medical Isotopes Production Act of 2012 and says, “The committee judges that there is a substantial (>50 percent) likelihood of severe molybdenum-99/technetium-99m supply shortages after October 2016, lasting at least until current global suppliers complete their planned capacity expansions.”

Mo-99 is used to produce Tc-99m, the most commonly used radioisotope worldwide (about half in the United States). The production and supply of radioisotopes iodine-131 (I-131) and xenon-133 (Xe-133) are also a concern.

Shortages of Mo-99 in recent years, due to reliance on aging reactors outside the United States, have led to major efforts around the globe to ensure a reliable supply. Since a major shortage of Mo-99 occurred in 2009, there has been pessimism about meeting future needs for Tc-99m.

The NAS report points out that 75 percent of the global supply of Mo-99 for medical use is produced using HEU targets; the remaining 25 percent is produced with low enriched uranium (LEU targets).

The U.S. Department of Energy’s National Nuclear Security Administration (DOE/NNSA) is providing matching funding opportunities for research and development of domestic Mo-99 production methods that do not use HEU. Four NNSA-supported projects are currently underway, and each project is intended to supply half or more of U.S. needs. However, the report states that substantial domestic supplies are unlikely to be available before 2018 due to technical, financial, regulatory and market challenges.

The study recommends that the U.S. government continue to work with the Canadian government to ensure that a plan is in place to restart Canadian supply if needed. Canada has said it will keep its reactor on stand-by until the end of March 2018, when it will shut down permanently.

Progress is being made toward eliminating the use of HEU for medical isotope production; global Mo-99 suppliers have committed to eliminating HEU use in reactor targets and medical isotope production facilities, and financial support from NNSA and technical support from U.S. national laboratories are facilitating domestic production efforts. However, the continued availability of Mo-99 produced with HEU is an impediment. Companies using LEU find themselves at a competitive disadvantage.

The NAS report recommends that the U.S. government and others should take additional actions to promote the wider use of non-HEU produced Mo-99/Tc-99m.

The report outlines additional steps that could be taken:

  • The Centers for Medicare & Medicaid Services (CMS) could continue to offer the $10 add-on reimbursement for Tc-99m from non-HEU sources until HEU sources are no longer available in the U.S. CMS could also accelerate the retrospective analysis of the costs of medical procedure that utilize Tc-99m from non-HEU sources;
  • NNSA could examine options to eliminate the availability of HEU targets for Mo-99 production to shorten the transition process. It might buy back U.S. origin HEU in raw or target form from global Mo-99 suppliers, once production with LEU targets is well established;
  • Technetium generator manufacturers and nuclear pharmacies could continue efforts to further increase the use of Mo-99 from non-HEU sources; and
  • The U.S. Congress could restrict, or place financial penalties on, the import of Mo-99 produced with HEU targets (once non-HEU sources are widely available).

Society of Nuclear Medicine and Molecular Imaging (SNMMI) President Sally W. Schwarz, MS, RPh, BCNP, professor of radiology at Washington University School of Medicine in St. Louis, agrees in general with the report’s assessment and also noted, “Development of these new, non-HEU production methods is costly, even when shared with governments. It will take time and incremental changes to reach a balance point of fair reimbursement for increased costs for all members of the supply chain including Mo-99 producers, generator manufacturers, nuclear pharmacies, hospitals and patients.”

Schwarz cautioned that the potential for short-term shortages is a real concern, but the global Mo-99 producers, processors and generator manufacturers, working with AIPES, will strive to manage any interim shortage problems that might occur.

She is optimistic overall about Mo-99/Tc-99m production through non-HEU means and the development of a domestic source of Mo-99. “The innovative, safer production methods and facilities that will be coming online over the next few years will certainly help ensure a safe, reliable supply of Mo-99.”

For more information: www.snmmi.org

Related Content

Australian Team Finds New Method for Producing PET Radiotracers in Higher Radiochemical Yields
News | Radiopharmaceuticals and Tracers | April 28, 2017
April 28, 2017 — Researchers at the Australian Nuclear Science and Technology Organisation (ANSTO) have led the devel
Sponsored Content | Videos | Nuclear Imaging | April 28, 2017
David Wolinsky, M.D., director of nuclear cardiology at Cleveland Clinic Florida and past-president of the American S
News | Prostate Cancer | April 24, 2017
April 24, 2017 — Cancer Targeted Technology recently announced it is focusing on small molecules that target pivotal
SPECT/CT Imaging Test Shown Accurate in Ruling Out Kidney Cancers
News | SPECT Imaging | April 24, 2017
The latest in a series of studies led by researchers at Johns Hopkins Medicine shows that addition of a widely...
University of Missouri Research Reactor Files to Start U.S. Production of Medical Isotopes
News | Radiopharmaceuticals and Tracers | April 13, 2017
The University of Missouri Research Reactor (MURR) and its partners Nordion and General Atomics (GA), announced in...
IBA Molecular and Mallinckrodt Nuclear Medicine Merge to Become Curium
News | Radiopharmaceuticals and Tracers | April 11, 2017
IBA Molecular announced that it has merged with previous acquisition Mallinckrodt Nuclear Medicine LLC to form the new...
FDG-PET, cell mutations, lung cancer patients, non-small cell lung cancer, NSCLC, Journal of Nuclear Medicine study

From left to right are patients with EGFR mutation, KRAS mutation, and EGFR– and KRAS– tumors, respectively. Stage I and III tumors are shown in the top and bottom rows, respectively. Arrows indicate the locations of the lung tumors. Credit: Stephen S.F. Yip, Ph.D., and Hugo Aerts, Ph.D., Dana-Farber Cancer Institute, Brigham and Women’s Hospital, and Harvard Medical School, Boston; John Kim, M.D., University of Michigan Health System, Ann Arbor, Mich.

News | PET Imaging | April 05, 2017
Researchers have used positron emission tomography (PET) to successfully identify genetic cell mutations that can cause...
GE Healthcare, HealthTrust, supply agreement, nuclear imaging, radiopharmaceuticals
News | Radiopharmaceuticals and Tracers | April 05, 2017
GE Healthcare has signed an agreement with HealthTrust, a group purchasing organization headquartered in Nashville,...
Northwestern Memorial Hospital, MR-PET scanner, first in Illinois, Siemens Biograph mMR
News | PET-MRI | March 31, 2017
Northwestern Memorial Hospital is now home to the Chicago area's first combined magnetic resonance (MRI) and positron...
News | Radiopharmaceuticals and Tracers | March 29, 2017
Advanced Accelerator Applications S.A. announced that its product NETSPOT (gallium Ga-68 dotatate) has been included in...
Overlay Init